These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 14512867)

  • 1. The role of ribavirin-induced mutagenesis in HCV therapy: a concept or a fact?
    Hong Z
    Hepatology; 2003 Oct; 38(4):807-10. PubMed ID: 14512867
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA.
    Kanda T; Yokosuka O; Imazeki F; Tanaka M; Shino Y; Shimada H; Tomonaga T; Nomura F; Nagao K; Ochiai T; Saisho H
    J Viral Hepat; 2004 Nov; 11(6):479-87. PubMed ID: 15500548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of hepatitis C virus genotype 2a replicon variants with reduced susceptibility to ribavirin.
    Hmwe SS; Aizaki H; Date T; Murakami K; Ishii K; Miyamura T; Koike K; Wakita T; Suzuki T
    Antiviral Res; 2010 Mar; 85(3):520-4. PubMed ID: 20043953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy.
    Hofmann WP; Polta A; Herrmann E; Mihm U; Kronenberger B; Sonntag T; Lohmann V; Schönberger B; Zeuzem S; Sarrazin C
    Gastroenterology; 2007 Mar; 132(3):921-30. PubMed ID: 17383421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
    Young KC; Lindsay KL; Lee KJ; Liu WC; He JW; Milstein SL; Lai MM
    Hepatology; 2003 Oct; 38(4):869-78. PubMed ID: 14512874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1b infection. No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy.
    Sugihara K; Orito E; Tanaka Y; Kato T; Lau JY; Ohno T; Hayashi K; Ogino M; Hirashima N; Sakakibara K; Mizuno Y; Kato H; Suzuki S; Ueda R; Mizokami M
    Intervirology; 2006; 49(6):319-26. PubMed ID: 16926544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis.
    Ortega-Prieto AM; Sheldon J; Grande-Pérez A; Tejero H; Gregori J; Quer J; Esteban JI; Domingo E; Perales C
    PLoS One; 2013; 8(8):e71039. PubMed ID: 23976977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.
    Yano Y; Seo Y; Miki A; Saito M; Kato H; Hamano K; Oya M; Ouchi S; Fujisawa T; Yamada H; Yamashita Y; Tani S; Hirohata S; Yoon S; Kitajima N; Kitagaki K; Kawara A; Nakashima T; Yu H; Maeda T; Azuma T; El-Shamy A; Hotta H; Hayashi Y;
    Int J Mol Med; 2012 Nov; 30(5):1048-52. PubMed ID: 22899224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the NS5A gene are associated with response to interferon+ribavirin combination therapy in patients with chronic hepatitis C virus 3a infection.
    Ullah S; Rehman HU; Idrees M
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1146-51. PubMed ID: 23611896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribavirin: is it a mutagen for hepatitis C virus?
    Perelson AS; Layden TJ
    Gastroenterology; 2007 May; 132(5):2050-2. PubMed ID: 17484896
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome.
    Mihm U; Hofmann WP; Welsch C; Polta A; Lengauer T; Zeuzem S; Sarrazin C; Herrmann E
    J Viral Hepat; 2010 Mar; 17(3):217-21. PubMed ID: 19758279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent.
    Mejer N; Galli A; Ramirez S; Fahnøe U; Benfield T; Bukh J
    Virology; 2020 Jan; 540():132-140. PubMed ID: 31778898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ribavirin on the hepatitis C virus (JFH-1) and its correlation with interferon sensitivity.
    Brochot E; Duverlie G; Castelain S; Morel V; Wychowski C; Dubuisson J; François C
    Antivir Ther; 2007; 12(5):805-13. PubMed ID: 17713164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.
    Lanford RE; Guerra B; Lee H; Averett DR; Pfeiffer B; Chavez D; Notvall L; Bigger C
    J Virol; 2003 Jan; 77(2):1092-104. PubMed ID: 12502825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potentiating effect of ribavirin on interferon in the treatment of hepatitis C: lack of evidence for ribavirin-induced viral mutagenesis.
    Schinkel J; de Jong MD; Bruning B; van Hoek B; Spaan WJ; Kroes AC
    Antivir Ther; 2003 Dec; 8(6):535-40. PubMed ID: 14760887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C.
    Asahina Y; Izumi N; Enomoto N; Uchihara M; Kurosaki M; Onuki Y; Nishimura Y; Ueda K; Tsuchiya K; Nakanishi H; Kitamura T; Miyake S
    J Hepatol; 2005 Oct; 43(4):623-9. PubMed ID: 16098627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.
    El-Shamy A; Shoji I; Saito T; Watanabe H; Ide YH; Deng L; Kawata S; Hotta H
    Microbiol Immunol; 2011 Jun; 55(6):418-26. PubMed ID: 21371092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin.
    Dal Pero F; Tang KH; Gerotto M; Bortoletto G; Paulon E; Herrmann E; Zeuzem S; Alberti A; Naoumov NV
    J Infect Dis; 2007 Oct; 196(7):998-1005. PubMed ID: 17763320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanisms of drug resistance in hepatitis viruses B and C].
    Yotsuyanagi H; Koike K
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():493-6. PubMed ID: 17455669
    [No Abstract]   [Full Text] [Related]  

  • 20. Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase.
    Ward CL; Dev A; Rigby S; Symonds WT; Patel K; Zekry A; Pawlotsky JM; McHutchison JG
    J Viral Hepat; 2008 Aug; 15(8):571-7. PubMed ID: 18363671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.